Puma Biotechnology Inc (PBYI) News

Puma Biotechnology Inc (PBYI): $3.20

0.09 (+2.89%)

POWR Rating

Component Grades








Add PBYI to Watchlist
Sign Up

Industry: Biotech




#25 of 352

in industry

Filter PBYI News Items

PBYI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PBYI News Highlights

  • For PBYI, its 30 day story count is now at 18.
  • Over the past 23 days, the trend for PBYI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about PBYI are III, EU and LUNG.

Latest PBYI News From Around the Web

Below are the latest news stories about PUMA BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate PBYI as an investment opportunity.

Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug

Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.

Yahoo | December 28, 2023

Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody

The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news.

Yahoo | December 28, 2023

Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate

The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.

Yahoo | December 26, 2023

Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis

Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.

Yahoo | December 26, 2023

Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program

Sanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint.

Yahoo | December 22, 2023

argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study

argenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls.

Yahoo | December 21, 2023

Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag

The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024.

Yahoo | December 20, 2023

Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA

The CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise.

Yahoo | December 20, 2023

Invivyd (IVVD) Surges on Positive Data From COVID-19 Study

Invivyd (IVVD) reports positive initial data from the phase III CANOPY study on VYD222 for the prevention of symptomatic COVID-19. Stock shoots up on the news.

Yahoo | December 19, 2023

Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GA

The CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines.

Yahoo | December 15, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!